Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.

Current drug targets - 1 Oct 2009

Meriggi F, Di Biasi B, Abeni C, Zaniboni A

Abstract excerpt

The anti-epidermal growth factor receptor monoclonal antibodies cetuximab and panitumumab have established efficacy as single agent and in combination with chemotherapy in advanced colorectal cancer. However, only a small percentage of unselected patients (around 10%) are responsive to these costly agents. Mutations in the KRAS gene are associated with resistance to both cetuximab and panitumumab and account for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Panitumumab

Share to Patient Selection

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19663767
DOI: 10.2174/138945009789577891

Genes

EGFR
KRAS
BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.PMID 19663767Read ↗

[Predictive factors of response to anti-EGFR treatments in colorectal cancer].Semantic proximity Read ↗

Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerSemantic proximity Read ↗

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.Semantic proximity Read ↗

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

[Anti-EGFR antibody therapy for colorectal cancer].Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.Semantic proximity Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.